Skip to content

Inspection prep notes · Quality system

Deviation investigations and root cause

Also called: deviation, root cause, investigation

FDA looks less at whether a deviation procedure exists than at whether deviations in manufacturing, equipment and the environment are recorded on time and investigated through to a supported cause and the full extent of impact. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Limit excursions and equipment problems were not opened as deviations

For example, you recovered 83 colony forming units, including mold, from sampling an operator’s neck in the ISO 7 area in (b)(4) . Your action level is (b)(4) or more colony forming units, but you did not initiate a deviation investigation.

FDA Warning Letter · Jubilant HollisterStier General Partnership · 2026-06-23

No documentation, deviation, investigation, or product impact assessment was initiated to determine the effect of the out-of-calibration thermometer on product quality.

FDA 483 · Galaxy Medical Products LLC · 2026-10-27

2Root causes were not supported by evidence

Your firm lacked timely and adequate media fill investigations. For instance, your root causes were unsupported and lacked effective corrective actions.

FDA Warning Letter · K.C. Pharmaceuticals, Inc. · 2026-08-18 · View document

The deviation fails to include enough information to support the root cause as a machine malfunction.

FDA 483 · Biomat USA, Inc. · 2026-10-20 · View document

3Investigations were not extended to other potentially affected batches

Your investigations into these complaints were inadequate, as you repeatedly failed to conduct thorough investigations, adequately identify root causes, provide scientific rationale for your conclusions, and extend investigations to other potentially affected batches.

FDA Warning Letter · CareFusion 213, LLC · 2026-05-05 · View document

Deviation investigation 300104231 failed to be extended into any other batches ofFlebogamma, specifically US marketed batches of Flebogamma tested for release during the period in question.

FDA 483 · Instituto Grifols, S.A. · 2026-10-27 · View document

4Deviations were not recorded and investigated in a timely manner

Specifically, your firm’s procedure for deviation management does not ensure timely documentation and assessment of quality events to determine potential impact on product quality.

FDA 483 · Seqirus Inc · 2026-10-26

The investigation of Deviation M24/06/21/01 did not take place in a timely manner.

FDA 483 · Serum Institute of India Pvt. Ltd. · 2026-10-26 · View document

5Recurring deviations were not traced to their causes and acted on

You failed to adequately investigate and implement corrective actions and preventive actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents.

FDA Warning Letter · Medline Inc · 2026-06-02

The firm has only recently started to trend and categorize deviations based on root cause and has only recently begun to implement a continuous improvement training but has not taken action to ensure that critical manufacturing steps are carried out effectively.

FDA 483 · IDT Biologika GmbH · 2026-10-26 · View document

Questions to check against your procedures

  1. Is a deviation investigation opened every time an environmental or personnel monitoring result exceeds the action level?
  2. When an out-of-calibration instrument is found to have been used, is it recorded as a deviation and a product impact assessment performed?
  3. Do deviation records contain enough information to support the stated root cause?
  4. Are deviation investigations extended to other batches that may have been affected?
  5. Does the procedure ensure that quality events are recorded when they occur and that investigations are completed in a timely manner?
  6. Are recurring deviations and contamination incidents trended by root cause and followed by action to prevent recurrence?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.